Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions

Clinical Chemistry

Volumn 51, Issue 4, 2005, Pages 695-707

  Le, Lyly ^a   Chi, Kim ^a   Tyldesley, Scott ^a   Flibotte, Stephane ^a   Diamond, Deborah L ^b   Kuzyk, Michael A ^a   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ISOPROTEIN; TUMOR MARKER;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DISEASE MARKER; HUMAN; IMMUNOASSAY; MALE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; ALGORITHMS; BONE NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID A PROTEIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 16244390914     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.041087     Document Type: Article

References (57)

1. Greenlee LK, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 2000;50:7-33.
2. Plesnicar S. The course of metastatic disease originating from carcinoma of the prostate. Clin Exp Metastasis 1985;3:103-10.
3. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
4. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Mars V, et al. Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506-13.
5. Bova GS, Chan-Tack KM, LeCates WW. Lethal metastatic human prostate cancer. In: Chung LWK, Isaacs WB, Simons JW, eds. Prostate cancer: biology genetics and new therapeutics. Totowa NJ: Humana Press, 2001:39-60.
6. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202.
7. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17:948-57.
8. Galasko CSB. The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert HA, eds. Bone metastasis, Vol. 6. Boston: GK Hall, 1981:49-63.
9. Zhau HE, Li CL, Chung LW. Establishment of a human prostate carcinoma skeletal metastasis model. Cancer 2000;88:2995-3001.
10. Huber PR, Schnell Y, Hering F, Rutishauser G. Prostate specific antigen. Experimental and clinical observations. Scand J Urol Nephrol Suppl 1987;104:33-9.
11. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
12. Wolff JM, Ittel T, Borchers H, Brauers A, Jakse G. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate. Urol Int 1998;61:12-6.
13. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Brinkman AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen response element. Mol Endocrinol 1991;5:1921-30.
14. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991;48:189-93.
15. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991;67:3057-64.
16. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58:4640-5.
17. Haq M, Goltzman D, Tremblay G, Brodt P. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 1992;52:4613-9.
18. Ueda T, Bruchovsky N, Sadar MD. Activation of the N-terminus of the androgen receptor by interleukin-6 via MARK and STAT3 signal transduction pathways cells. J Biol Chem 2002;277:7076-85.
19. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277:38087-94.
20. Blaszczyk N, Masri B, Mawji NR, Ueda T, McAlinden G, Duncan CP, et al. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 2004;10:1860-9.
21. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54:5474-8.
22. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999;6:487-502.
23. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:181-7.
24. Hoosein N, Abdul M, McCabe R, Gero E, Deftos L, Banks M, et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostatic carcinoma. Urol Oncol 1995;1:246-51.
25. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-9.
26. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-33.
27. Wehbi NK, Dugger AL, Bonner RB, Pitha JV, Hurst RE, Hemstreet GP. Pan-cadherin as a high level phenotypic biomarker for prostate cancer. J Urol 2002;167:2215-21.
28. Stenman U, Finne P, Zhang W, Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology 2000;56:893-8.
29. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001;12:S153-7.
30. Mackintosh J, Simes J, Raghavan D, Pearson B. Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". Br J Urol 1990;66:88-93.
31. Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998;34:252-9.
32. Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 1987;166:368-79.
33. Neuhoff V, Arold N, Taube D, Ehrhardt W. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988;9:255-62.
34. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 2000;16:906-14.
35. Witten IH, Frank E. Data mining: practical machine learning tools with Java implementations. San Francisco: Morgan Kaufmann, 2000:371pp.
36. Xiao Z, Jiang X, Beckett M, Wright GL Jr. Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. Prot Expression Purif 2000;19:12-21.
37. Diamond DL, Kimball JR, Krisanaprakornkit S, Ganz T, Dale BA. Detection of β-defensins secreted by human oral epithelial cells. J Immunol Methods 2001;256:65-76.
38. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
39. Raynes JG, Eagling S, McAdam KP. Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 1991;83:488-91.
40. Urwin GH, Percival RC, Yates AJ, Watson ME, Couch M, McDonald B, et al. Biochemical markers and skeletal metabolism in carcinoma of the prostate. Use of decision matrix theory and ROC analysis. Br J Urol 1985;57:711-4.
41. van Delft JH, Baan RA, Roza L. Biological effect markers for exposure to carcinogenic compound and their relevance for risk assessment. Crit Rev Toxicol 1998;28:477-510.
42. Collins AR. Molecular epidemiology in cancer research. Mol Aspects Med 1998;19:359-432.
43. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
44. Berruti A, Cerutti S, Fasolis G, Sperone P, Tarabuzzi R, Bertetto O, et al. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy. Gruppo Onco Urologico Piemontese (G.O.U.P). Anticancer Res 1997;17:4697-702.
45. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
46. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43.
47. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
48. Jr GW, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, et al. Proteinchip(R) surface enhanced laser oesorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999;2:264-76.
49. Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49:752-60.
50. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003;40:267-79.
51. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein in normal and disease states. Curr Opin Hematol 2000;7:64-9.
52. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984;19:193-8.
53. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 1998;46:1377-84.
54. Rosenthal CJ, Sullivan LM. Serum amyloid A to monitor cancer dissemination. Ann Intern Med 1979;91:383-90.
55. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity stage primary site and prognosis. J Clin Pathol 1986;39:794-7.
56. Kaneti J, Winikoff Y, Zimlichman S, Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 1984;12:239-41.
57. Srinivas PR, Srivastava S, Hanash S, Wright GL. Proteomics in early detection of cancer. Clin Chem 2001;47:1901-11.